GALWAY, Ireland--(BUSINESS WIRE)--Signum Surgical, a medical technology company dedicated to advancing the treatment of colorectal diseases, today announced the publication of first-in-human clinical ...
The U.S. FDA granted Signum Surgical Ltd. de novo marketing clearance for its Biohealx technology as a treatment for anal fistula. Biohealx is a single use, bioabsorbable implant, designed to not only ...
Anal fistula management remains a challenging surgical domain where the primary goals are the eradication of infection, minimisation of recurrence, and preservation of sphincter integrity. Standard ...
Pivotal data supports U.S. FDA De Novo clearance and sets the stage for U.S. launch GALWAY, Ireland--(BUSINESS WIRE)-- Signum Surgical, a medical technology company dedicated to advancing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results